We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
KYTX

Price
3.07
Stock movement up
+0.15 (4.37%)
Company name
Kyverna Therapeutics, Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
154.82M
Ent verdi
-
Pris/omsetning
-
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-48.71%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2025-09-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UTBYTTE

KYTX betaler ikke utbytte

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok-
EV i forhold til salg-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning3.34
Daglig høy3.58
Daglig lav3.27
Daglig volum226K
Tidenes høyeste30.10
1 år analytikerestimat17.20
Beta-
EPS (TTM)-
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon12 Nov 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
KYTXS&P500
Nåværende prisfall fra toppnotering-89.80%-3.04%
Høyeste prisfall-93.92%-56.47%
Dato for høyeste fall16 Apr 20259 Mar 2009
Gj.snittlig fall fra topp-72.37%-10.99%
Gj.snittlig tid til ny topp192 days12 days
Maks tid til ny topp384 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

SELSKAPSOPPLYSNINGER
KYTX (Kyverna Therapeutics, Inc. Common Stock) company logo
Markedsverdi
154.82M
Markedsverdi kategori
Small-cap
Beskrivelse
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Ansatte
129
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ VIRKSOMHETEN
Loading...